CM
ANIP icon

Capula Management’s ANI Pharmaceuticals ANIP Stock Holding History

Capula Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-16,740
Closed -$972K – 315
2023
Q3 		$972K Buy
+16,740
New +$966K 0.02% 219

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capula Management's ANIP Position: Q4 2023 in Review

Capula Management sold out of ANI Pharmaceuticals (ANIP) in Q4 2023, closing a stake of 16,740 shares — an estimated $972K sold.

Capula Management first reported a position in ANIP in Q3 2023 and held it in 1 quarter. The position peaked at $972K in Q3 2023. 181 funds tracked by Wall St. Rank hold ANIP as of Q4 2023.

  • Capula Management reported no remaining ANI Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Capula Management sold 16,740 ANI Pharmaceuticals shares in Q4 2023, an estimated $972K.
  • Capula Management first reported a position in ANI Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Capula Management's ANI Pharmaceuticals position peaked at $972K in Q3 2023.
  • 181 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2023.

Based on Capula Management's 13F filing for Q4 2023, filed 12 Feb 2024.